002901 Double Medical Technology Inc.
- 32.12
- +0.83+2.65%
Double Medical Technology Inc. News
Dabo Healthcare (002901.SZ): Net profit of 61,728,900 yuan in the first quarter increased 6.05% year-on-year
On April 29, Ge Longhui (002901.SZ) released its report for the first quarter of 2024, with operating income of 427 million yuan, up 9.17% year on year; net profit attributable to shareholders of listed companies was 61.7289 million yuan, up 6.05% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 49.363 million yuan, up 4.48% year on year; basic earnings per share were 0.15 yuan.
League of Nations Securities: The impact of collection is gradually clear, and the localization rate of the orthopedic industry continues to rise
Orthopedics is expected to usher in restorative growth
Dabo Healthcare (002901.SZ): 2023 net profit of 589.725 million yuan, a year-on-year decrease of 36.28%
Gelonghui, March 29丨Dabo Healthcare (002901.SZ) released its 2023 annual report. In 2023, the company achieved operating income of 1,533 billion yuan, an increase of 6.90%; net profit attributable to shareholders of listed companies was 589.725 million yuan, a year-on-year decrease of 36.28%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 10.551 million yuan, a year-on-year decrease of 88.45%; basic earnings per share were 0.14 yuan
Dabo Medical (002901.SZ): Currently, there is no application of medical information+AI medicine in product development
Gelonghui March 20 丨 An investor asked Dabo Healthcare (002901.SZ) on the investor interactive platform, “The company is a leading orthopedic enterprise. Does the company currently have any product development aspects, apply medical information+AI medicine?” The company replied that the company currently does not apply medical information+AI medicine in product development.
Dabo Healthcare (002901): The impact of collection is gradually being clarified. Focus on marginal changes in the company's operations
The performance was in line with expectations. The impact of collection was gradually cleared in the first three quarters of 2023. The company achieved revenue of 1,125 billion yuan, a year-on-year decrease of 8.86%; net profit to mother was 98 million yuan, a year-on-year decrease of 54.03%. In the third quarter,
Dabo International, the majority shareholder of Dabo Medical (002901.SZ), reduced its holdings by a total of 2.21%, and the stock reduction period expired
Dabo Healthcare (002901.SZ) issued an announcement. As of the disclosure date of this announcement, Dabo International's current holdings reduction plan is for...
Guojin Securities: Announcement of the results of the fourth batch of consumables proposed for domestic procurement, optimistic about the continued release of artificial crystal products
It is expected that the products of domestic listed artificial crystals will continue to be released, and domestic replacement of bifocal artificial crystals will begin.
Guotai Junan: Moderate election rules and national adoption are expected to accelerate the number of domestic companies admitted to hospital
Guotai Junan released a research report saying that the localization rate of sports medicine has increased dramatically, and Guotai Junan is expected to accelerate the number of domestic companies admitted to hospital.
Dabo Healthcare (002901.SZ): Net profit for the third quarter was 4.180,600 yuan, down 87.10% year-on-year
GLONGHUI, Oct. 26 | Dabo Healthcare (002901.SZ) announced its report for the third quarter of 2023. Revenue for the reporting period was 376 million yuan, down 7.63% year on year; net profit attributable to shareholders of listed companies was 4.180,600 yuan, down 87.10% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -116.753 million yuan; basic earnings per share were 0.0101 yuan.
[Instant Analysis of BT Financial Report] Dabo Medical's 2023 Interim Report: Net asset growth is steady, gross profit margin and net interest rate are under pressure, goodwill is stable, and the balance ratio has risen
Dabo Medical Technology Co., Ltd. (stock code: 002901) is a company focusing on the production, development and sales of high-value medical consumables. The company's main products are widely used in fracture repair, spinal disease treatment, joint replacement, sports medicine and dental implants. In the 2023 semi-annual report, there have been some changes in the company's financial position. First, as can be seen from the balance sheet, Dabo Medical's total assets at the end of the period were 4.315 billion yuan, up from 3,938 billion yuan at the beginning of the period. The total debt increased from 831 million yuan at the beginning of the period to 1,121 million yuan at the end of the term
Anxin Securities: Orthopedics has gone beyond the policy bottom to focus on high-quality domestic leaders in key segmented tracks
Anxin Securities released a research report saying that orthopedics has left the bottom of the policy, and the probability that the policy will be further tightened or prices will drop further is low.
Anxin Securities: At the bottom of the orthopedic collection policy, it is now recommended to focus on Weigao Orthopedics (688161.SH), etc.
Anxin Securities believes that orthopedics has reached the bottom of the policy, that there is a low probability that the policy will be further tightened or that prices will drop further in the future, and prices have basically stabilized.
Dabo Healthcare (002901): Trauma collection bid renewal rules gently focus on the company's marginal changes
Investment points Trauma collection and bid renewal rules are moderate, and the bid price of the product may increase: On September 18, the Beijing-Tianjin-Hebei Pharmaceutical Joint Procurement Platform issued the “Provincial Alliance Notice on Centralized Procurement of Orthopedic Trauma Medical Consumables”. The renewal rules are relatively moderate, and
Anxin Securities: Trauma collection renewal rules focus more gently on valuation repair opportunities for leading targets
It is recommended to focus on investment opportunities brought about by increased performance growth expectations and valuation repairs, which are the main targets of the orthopedic circuit.
Dabo Medical (002901.SZ) shareholder Dabo International and its co-actor Zhao Shaomei reduced their holdings by a total of 9.88 million shares, accounting for 2.39% of the total share capital
Dabo Medical (002901.SZ) issued an announcement. The company recently received the shareholder Dabo Medical International Investment Co., Ltd...
Dabo Healthcare (002901): Under the influence of mining, performance continues to be under pressure, and overseas growth is impressive
Guide to this report: Under the influence of collection, the company's performance continues to be under pressure. After the impact of collection is fully reflected, it is expected to grow steadily on a new base. Non-orthopedic business and overseas business are expected to bring about a second growth curve and maintain ratings growth. Key points of investment: Maintaining “growth”
Guoxin Securities: A new stage of development may be ushered in after full coverage of the three fields of orthopedics
In the post-collection era, it is expected to go to battle lightly, help improve the penetration rate of clinical treatment, and accelerate import substitution.
Dabo Healthcare (002901.SZ) plans to relinquish preferential purchasing rights of shares in subsidiary Anderthink Popular Scheider
According to the Zhitong Finance App, Dabo Healthcare (002901.SZ) announced that the company's affiliated corporation Changdu Dabo Trade Medical Investment Management Co., Ltd. (“Dabo Commerce”) plans to take shares in Beijing Anderthink Technology Co., Ltd. (“Andthink”), a holding subsidiary of the Company, and Scheider (Xiamen) Medical Equipment Co., Ltd. (“Ed”). The company intends to relinquish priority purchasing rights in this transaction. According to reports, Anderthink Popular Scheider, a holding subsidiary of the company, is mainly engaged in R&D, production, and sales of intervertebral forressure equipment and minimally invasive surgical consumables. Currently, some provinces and cities are involved in the R&D, production, and sales of these equipment and minimally invasive surgical instruments.
Dabo Healthcare (002901.SZ): The majority shareholder Dabo Trading plans to participate in Schaide's shares
Gelonhui, June 26, 丨 Dabo Healthcare (002901.SZ) announced that the fourth meeting of the third board of directors and the third meeting of the third board of supervisors held on June 26, 2023 deliberated and passed the “Proposal on Major Shareholders' Participation in the Company's Subsidiaries and Joint Investment with Related Parties”. The shareholder of Beijing Andesp Technology Co., Ltd. (“Andersapp”), a holding subsidiary of the company holding 51% of the company's shares, Xiamen FittiSky Technology Partnership (Limited Partnership) (“FitSky”) intends to transfer 9% of Andesipp's shares to Dabo Trading, the majority shareholder of the company
Dabo Healthcare (002901.SZ): Some directors and supervisors plan to reduce their holdings by no more than 90,000 shares
Glonway, June 26丨Dabo Healthcare (002901.SZ) announced that the company recently received a “Notice of Shareholding Reduction Plan” issued by some of the company's directors and supervisors. Mr. Luo Jiong, the company's director and general manager, plans to reduce the number of company shares by no more than 70,000 shares through centralized bidding transactions, accounting for 0.0169% of the company's total shares; R&D Director Han Shaojian, Executive Director Mr. Ruan Dongyang, and Supervisory Board Chairman Ms. Zhan Huanhuan plan to reduce the number of shares held by no more than 20,000 shares of the company's total shares through centralized bidding transactions. Not separately Over 0.0048%;
Analysis
Price Target
No Data
